Sign In
Buy PFE
$26.04
+0.345 (+1.34%)
At Close: Jun 05, 2026
3 Stocks to Buy Following Robust Quarterly Results
11:15am, Wednesday, 30'th Oct 2024
Throughout the Q3 reporting cycle, several companies, including Pfizer, Philip Morris, and Tenet Healthcare, have stolen the spotlight, with each raising guidance.
Here's Why Pfizer (PFE) is a Strong Value Stock
10:40am, Wednesday, 30'th Oct 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Pfizer Stock Tumbled on Tuesday
07:06pm, Tuesday, 29'th Oct 2024
The specter of an activist investor looms over the company.
Pfizer CEO says he welcomes good ideas as Starboard ups pressure on company
06:30pm, Tuesday, 29'th Oct 2024
In a Tuesday interview with CNBC's Jim Cramer, Pfizer CEO Albert Bourla struck a positive tone about activist investor Starboard Value, saying he agreed with some of its criticisms, but maintained tha
Pfizer, Inc. (PFE) Q3 2024 Earnings Call Transcript
05:16pm, Tuesday, 29'th Oct 2024
Pfizer, Inc. (NYSE:PFE ) Q3 2024 Earnings Conference Call October 29, 2024 10:00 AM ET Company Participants Francesca DeMartino - Chief Investor Relations Officer & SVP Albert Bourla - Chairman & CEO
Pfizer CEO Defends Record Against Activist Attack
03:53pm, Tuesday, 29'th Oct 2024
Pfizer shares have performed abysmally in recent years, as the company has failed to win investor confidence ahead of a wave of patent expirations coming by the end of the decade.
Pfizer's Oncology Triumphs Keep Investors Hooked Amid Market Volatility
03:32pm, Tuesday, 29'th Oct 2024
Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for the third quarter of 2024 by a large margin. Tafamidis franchise sales were $1.45 billion in Q3 2024
Pfizer's Strong Quarter Bolsters CEO's Comeback Efforts
03:19pm, Tuesday, 29'th Oct 2024
The pharmaceutical company reported its third consecutive quarter with positive results.
Pfizer Results May Temper Efforts for Shakeup Demanded by Activist Investor
03:05pm, Tuesday, 29'th Oct 2024
Shares of Pfizer (PFE) fell Tuesday as a strong earnings report is seen as likely to limit activist investor Starboard Value from driving major changes at the drugmaker.
Pfizer Delivers Knockout Q3 Earnings Results, But Investors Are Unimpressed
02:30pm, Tuesday, 29'th Oct 2024
Pfizer's Q3 earnings smashed analysts' expectations, driven by a significant increase in COVID-related revenues, but the market remains skeptical about long-term growth. Despite strong financials and
Pfizer's Q3 Earnings Beat, Paxlovid Drives Sales Guidance Increase
12:25pm, Tuesday, 29'th Oct 2024
PFE beats third-quarter estimates for earnings and sales. It raises 2024 earnings and revenue expectations.
Pfizer (PFE) Reports Q3 Earnings: What Key Metrics Have to Say
10:35am, Tuesday, 29'th Oct 2024
The headline numbers for Pfizer (PFE) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates
08:56am, Tuesday, 29'th Oct 2024
Pfizer (PFE) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to loss of $0.17 per share a year ago.
Pfizer ups guidance as demand for Covid-19 products grows
08:42am, Tuesday, 29'th Oct 2024
Pfizer Inc (NYSE:PFE, ETR:PFE) has lifted full-year revenue guidance on the back of a rebound in demand for its Covid-19 products. Revenue is expected to sit between $61 billion and $64 billion over t
Pfizer Lifts Revenue Outlook, McDonald's Sees U.S. Sales Growth in Q3
07:50am, Tuesday, 29'th Oct 2024
Pfizer Q3 earnings beat expectations, driven by Paxlovid sales. Cost-saving goals aim for $4B by 2027 as Covid demand slows.
